BH3 mimetics to individual anti-apoptotic proteins were more successful, and the most important breakthrough was the approval of venetoclax, a selective Bcl-2 inhibitor, for the treatment of patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) (for the latter, in combination with azacitidine, decitabine, or low-dose cytarabine) [24]. The gene discussed is BCL2; the disease is acute myeloid leukemia.